[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-surgery":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,84,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100652425","wearable-supported-prehabilitation-and-rehabilitation-for-patients-undergoing-surgery-for-pancreatic-cancer-100652425",false,"NCT07772258","Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer","Perioperative Optimisation and Wearable Remote Monitoring of Pancreatic Cancer","POWR-PaC","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Able to provide informed consent.\n* Able to use the study devices independently or with support from a carer.\n* Approved for pancreatic cancer surgery, including patients undergoing surgery for:\n\nPancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).\n\n* Clinically stable and considered suitable to participate in the prehabilitation and rehabilitation programme.\n* Owns a smartphone or tablet device\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent.\n* Lacks capacity to provide informed consent.\n* Unstable angina pectoris.\n* Recent myocardial infarction.\n* Recent cerebrovascular accident (stroke).\n* New cardiac arrhythmia.\n* Social, physical, mental health, or substance misuse issues that, in the opinion of the investigator, would jeopardise adherence to study procedures or study contact.\n* No infrastructure for remote monitoring (no access to either mobile signal or Wi-Fi).\n* Clinically unstable or likely to require hospital admission within the next 72 hours.\n* Unable to use the study devices and no carer or support person is available to assist.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic\u002Fperiampullary conditions.\n\nThe main questions it aims to answer are:\n\nDoes a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?\n\nResearchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.\n\nParticipants will:\n\nProvide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.\n\nWear a Corsano CardioWatch device to continuously monitor physiological and activity data.\n\nUse home monitoring equipment, including weight scales and blood pressure monitoring devices.\n\nComplete questionnaires and participant logs during prehabilitation and recovery.\n\nReceive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.\n\nOptionally participate in a focus group to discuss their experiences of wearable-enabled care.",[27,28,29,30,31],"Pancreatic Cancer","Pancreatic Neoplasms","Periampullary Carcinoma","Pancreatic Surgery","Perioperative Care",[27,30,31,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Rehabilitation","Prehabilitation","Exercise","Nutrition","Wearables","Remote Monitoring","Digital Health","Mobile Health","Recovery of Function","Patient Monitoring","Telemedicine","Surgical Oncology","PROMS","Electronic Devices","NOT_YET_RECRUITING","2026-08-13",{"date":50,"type":51},"2026-08-19","ACTUAL",{"date":53,"type":21},"2026-10-01",{"date":55,"type":21},"2028-09-30",{"name":57,"class":58},"Manchester University NHS Foundation Trust","OTHER_GOV",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100639348","salvaged-red-blood-cell-transfusion-during-pancreatic-adenocarcinoma-operations-100639348","NCT07598357","Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form. Able to understand their disease and the exploratory nature of sRBC transfusion during surgery for this histology.\n2. Patient is 18 years of age or older\n3. Patient has a diagnosis of cytologically or pathologically confirmed pancreatic adenocarcinoma\n4. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Patient has an American Society of Anesthesiologists (ASA) classification of physical health status of 1-4\n6. Life expectancy of greater than six months\n7. Hemoglobin \\> 8.9 g\u002Fdl\n8. Platelet count greater than 200,000\u002Fmm3\n9. International Normalization Ratio ≤1.8\n10. Total serum bilirubin ≤ 2 mg\u002FdL\n11. Serum creatinine ≤ 1.5 mg\u002Fdl\n12. Recovered from any hematologic toxicity less than grade 3 from all prior chemotherapy or radiotherapy, and be at least 14 days past the date of their last treatment.\n\nExclusion Criteria:\n\n1. Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure.\n2. History of congestive heart failure and\u002For an LVEF \\\u003C40%.\n3. Metastases\n4. Active systemic infections, hematological diseases, coagulation disorders or other major medical illnesses of the cardiovascular, hepatic, renal, respiratory or immune system.\n5. Patients with transabdominal drains, or peripancreatic abscess or fluid collections on cross-sectional imaging.",{"count":66,"type":21},40,[24],"The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery.\n\nPrimary Objective:\n\n1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.\n2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion.\n3. To summarize rates and timing of AEs in the first 7 post-operative days.\n\nSecondary Objectives:\n\n1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room.\n2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.",[30],[71,72],"Cell Salvage","Transfusion","2026-05-14",{"date":75,"type":51},"2026-05-20",{"date":77,"type":21},"2026-06",{"date":79,"type":21},"2031-06",{"name":81,"class":82},"NYU Langone Health","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":103,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":83},"100567777","intra-abdominal-hypertension-and-abdominal-compartment-syndrome-in-patients-after-pancreatic-procedures-100567777","NCT06672601","Intra-abdominal Hypertension and Abdominal Compartment Syndrome in Patients After Pancreatic Procedures.","The HYPA Study: Intra-abdominal Hypertension and Abdominal Compartment Syndrome in Patients Undergoing Open and Robotic Pancreatic Procedures","HYPA","Inclusion Criteria:\n\n* Patients ≥ 18-year-old\n* Indication for elective pancreatic procedure\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old.\n* Contraindication for urinary catheter placement.\n* Refusal to participate in the study.",{"count":93,"type":21},150,"OBSERVATIONAL","This study investigates the development of intra-abdominal hypertension and compartment syndrome in patients undergoing elective pancreatic procedures. Main objective is to determine the proportion of patients after pancreatic operation who develop elevated intra-abdominal pressure and assess its association with postoperative complication rates. Another goal of the study is to compare open versus robotic pancreatic procedures regarding the occurrence of intra-abdominal hypertension and abdominal compartment syndrome.",[97,98,30,99,100,101,102],"Intra Abdominal Pressure","Abdominal Compartment Syndrome","Pancreatic Fistula After Pancreaticoduodenectomy","Delayed Gastric Emptying","Anastomotic Leaks","Overload Fluid",[104,105,106,107],"Intra-abdominal hypertension","Compartment syndrome","Pancreatic surgery","Robotic surgery","2024-11-07",{"date":110,"type":51},"2024-11-08",{"date":112,"type":21},"2025-01-01",{"date":114,"type":21},"2028-03-31",{"name":116,"class":82},"Charles University, Czech Republic",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":94,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":83},"100545396","italian-registry-of-minimally-invasive-pancreatic-surgery-100545396","NCT06381362","Italian Registry of Minimally Invasive Pancreatic Surgery","Italian Registry of Minimally Invasive Pancreatic Surgery (IGOMIPS)","IGOMIPS","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Underwent minimally invasive pancreatic surgery\n\nExclusion Criteria:\n\n* Pregnant woman\n* Minor or unable to give informed consent",{"count":126,"type":21},2300,"3 Months","Assess the prevalence of minimally invasive pancreatic surgery in the country and its outcomes",[30],"RECRUITING","2024-04-22",{"date":133,"type":51},"2024-04-24",{"date":135,"type":51},"2019-02-28",{"date":137,"type":21},"2029-02-28",{"name":139,"class":82},"Associazione Italiana per lo Studio del Pancreas"]